Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:46:38.375Z.
Consensus retrieved: 2026-10-06T10:26:31.744Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:46:38.375Z.
Quote observation: 2026-10-06T19:45:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 06562fb702a0da71b906a258253127b31d640f45e795332ac5785183133d8a11
Forward PE Ratio (N/A) = Dated Quote Price ($21.91) / Consensus Forward EPS ($7.36)
FORWARD PE RATIO
N/A
Collegium Pharmaceutical, Inc.
Market Cap
$710.66M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Collegium Pharmaceutical, Inc. (COLL) | $710.66M | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $713.58M | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $701.89M | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $722.21M | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $725.01M | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $689.85M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $688.55M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $688.40M | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $688.30M | N/A |
| Verastem, Inc. (VSTM)vs › | $684.40M | N/A |
Trailing P/E
17.7
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $7.36 implies +493.5% EPS growth vs the reported trailing $1.24.
At the dated quote price of $21.91, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $7.36 | $6.82 – $7.64 | 4 | 3.0x |
| 2027-12-31 | $6.68 | $5.23 – $8.20 | 4 | 3.3x |
| 2028-12-31 | $6.33 | $5.15 – $7.50 | 2 | 3.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
